News 
Market Data 
Discover
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
|
Followers
|
10
|
Posters
|
|
|
Posts (Today)
|
0
|
Posts (Total)
|
333
|
|
Created
|
12/14/06
|
Type
|
Free
|
| Moderators | |||
Deltagen is a leading provider of drug discovery tools and services to the biopharmaceutical industry. Deltagen offers a suite of programs designed to enhance the efficiency of drug discovery including access to biological models as well as both small-molecule and secreted protein drug targets. In addition, Deltagen offers extensive target validation data in the areas of immunology and metabolic diseases. Deltagen's products and programs have been validated by customers and partners such as Eli Lilly & Co., GlaxoSmithKline, Merck & Co., Millennium Pharmaceuticals and Pfizer.
Deltagen’s unique systems biology approach is designed to help clear the first and major hurdle of drug target discovery: lead validation. Our high-throughput in vivo mammalian knockout technology enables us to identify and validate the utility of genomic targets within a living model at an extraordinary scale and speed. Using our proprietary tools, we believe we can uncover clinically relevant drug targets more efficiently and earlier in the discovery process.
The scientists in our Target Discovery Program have developed methods to discover the gene function of novel drug targets and to understand disease pathways as we strive to accelerate the development of meaningful, commercially promising small-molecule and secreted-protein therapies. Our proprietary technology platforms serve the drug discovery efforts of our pharmaceutical partners and customers.
Snapshot Information
June 27, 2003 Files Chapter 11 BK ~ Lexicon Genetics sues Deltagen over royalties
Nov 15, 2005 Court Approves reorganization
March 14, 2005 Lexicon and Deltagen Settle diputes, Deltagen pays 4Million cash payment
Sept 2005 NIH gives 3 year contract, valued up to $25 Million
Sept 2005 (CRL) Charles River Laboratorys becomes exclusive custodian of world wide distributor of Deltagens repository.
Sept 30 2005 NIH orders $5.16 Million worth of knockout mouse
Nov 15 2005 Court Approves, paying creditor claims 100% and equity preserved intact.
Nov 29 2005 Court Appointed Reorganization effective.
Dec 2005 CEO resigns - Lawrence Hill, VP I&L Robert Driscoll becomes CEO and President and Secretary
Dr. Winston Thomas - elected COO
Dr. Shera Kash - elected VPO
Dr. Driscoll, Mr. Hill, Dr. Chambon, Mr. Hernon - elected to BOD
-----------------------------------------------------------------------------------------------------------------
Jan 2006 NIH pays $1.93 Million
Mar 31 2006 Company closes Chapter 11 BK with all contested claims resolved.
Jan-Feb-Mar ~ brings in $1.8M - 431K net
$1.548M - expenses to salaries, 3rd-party royaty, patent prosecution, legal fees
Cash on hand $10.392 Million.
Jun 30 2006 $3.749 Million Revenue
NIH pays $3.2Million per 3 year contract
$0.500 Million Revenue in Access Fees
$1.4Million Net
Cash on hand $10.789Million
July 2006 Hire investment banking firm to assist strategic alternatives or sale of company.
Sept 30 2006 $0.970 Million Revenue
$0137 net
Cash on hand $11.993Million
Oct 2006 Deltagen enters agreement to 1 time buyout of DeltaBase collborators
Nov 2006 BOD terminate Investment Banking option.
Deltagen moves to new facilities: The Artium, 1900 South Norfolk St. Ste 105, San Mateo, Ca.
Dec 2006 Divy of .20 per share reduces cash by $7.7Million
Cash on hand $4.29Million
Corporate Headquarters
1031 Bing Street
San Carlos, CA 94070
Tel 650-569-5100
New Corporate Headquarters
effective - Jan 1, 2007
The Atrium
1900 South Norfolk Street, Suite 105,
San Mateo, CA 94403.
Products and Programs
Winston Thomas, PhD.
Chief Operating Officer
Tel 650-569-5412
deltaone@deltagen.com
What they do....
Deltagen’s unique systems biology approach is designed to help clear the first and major hurdle of drug target discovery: lead validation. Our high-throughput in vivo mammalian knockout technology enables us to identify and validate the utility of genomic targets within a living model at an extraordinary scale and speed. Using our proprietary tools, we believe we can uncover clinically relevant drug targets more efficiently and earlier in the discovery process.
Product Line
Since late 2005, Deltagen has had a collaboration with Charles River Laboratories of Wilmington, Massachusetts (NYSE: CRL). Charles River Laboratories, a global provider of solutions that advance the drug discovery and development process for the biopharmaceutical industry, is the exclusive custodian and worldwide distributor of Deltagen's repository of knockout mouse materials
Reference
http://www.criver.com/
Press Releases and Other Information
http://www.deltagen.com/pressreleases/pressreleases.html
OFFICERS
Robert J. Driscoll, J.D., Ph.D.
President and Chief Executive Officer
Robert Driscoll, J.D., Ph.D., President and Chief Executive Officer since 2005, formerly served as the company's Vice President, Intellectual Property & Legal Affairs from 2003 until 2005 and as Associate General Counsel. Prior to joining Deltagen in 1999, Dr. Driscoll was a patent and intellectual property attorney with the law firm of Pillsbury Madison & Sutro LLP. Dr. Driscoll received his Ph.D. in Chemistry from the California Institute of Technology and his J.D. from Loyola Law School. Dr. Driscoll also sits on the company's Board of Directors.
Winston Thomas, Ph.D.
Chief Operating Officer
Winston Thomas, Ph.D., Chief Operating Officer since November 2005, formerly served as the company's Vice President, Scientific Operations from 2003 until November 2005 and as Associate Director and Senior Director of Molecular Biology. Prior to joining Deltagen in 1999, Dr. Thomas was a Senior Scientist at Mercator Genetics, Inc. from 1993 to 1999 and was a postdoctoral fellow at Genentech. Dr. Thomas received his Ph.D. in Cellular and Developmental Biology from Harvard University and his B.Sc. from the University of Utah.
Daniel Ratto
Chief Financial Officer
Daniel Ratto, Chief Financial Officer since 2003, has over 20 years of experience in various financial positions. For the last 16 years, Mr. Ratto has worked as a consultant in the fields of turnarounds, bankruptcy, restructuring, accounting and finance, having worked for a wide variety of companies.
BOARD of DIRECTORS
Constantine E. Anagnostopoulos, Ph.D.
Constantine Anagnostopoulos is Deltagen's Chairman of the Board. Dr. Anagnostopoulos is a retired corporate officer of Monsanto Company, a former managing partner of Gateway Associates, a Missouri-based venture capital firm, and the recently retired lead director of Genzyme Corporation. At Monsanto he served as Director of Research, Head of the New Enterprise Division, General Manager of a number of operating divisions and Chairman, President and CEO of Monsanto Europe-Africa-Middle East. He presently sits on the board of five biopharmaceutical companies, including Dyax Corporation. Dr. Anagnostopoulos received his Ph.D. in Organic Chemistry from Harvard University and is a graduate of the Executive Program in Business Administration of Columbia University. He has served on the Presidential Council on Innovation.
Robert J. Driscoll, J.D., Ph.D.
Robert Driscoll is Deltagen's President, Secretary and Chief Executive Officer. Dr. Driscoll served previously as Deltagen's Vice President, Intellectual Property & Legal Affairs and Associate General Counsel. Prior to joining Deltagen, Dr. Driscoll was a patent and intellectual property attorney with the law firm of Pillsbury Madison & Sutro LLP. Dr. Driscoll received his Ph.D. in Chemistry from the California Institute of Technology and his J.D. from Loyola Law School.
Martin J. Hernon
Marty Hernon is a General Partner of Boston Millenia Partners. From 1994 to 1997, Mr. Hernon was a Principal at Boston Capital Ventures. Previously, he was Assistant General Counsel for Lifetime Corporation, an alternate site healthcare services business, and an attorney in the Business Department at Warner & Stackpole/Kirkpatrick & Lockhart, a Boston law firm. Mr. Hernon received a B.A. in Economics from Boston College, an M.A. in Economics from the University of Maryland and a J.D. from Georgetown University.
Thomas A. Penn, J.D., M.B.A.
Thomas Penn is a Partner of Meridian Venture Partners. From 1998 until 2000 Mr. Penn was a partner of Boston Millennia Partners. From 1994 until 1998, Mr. Penn served as President and Chief Executive Officer of Tektagen, Inc. Prior to joining Tektagen, Mr. Penn was President of Independence Ventures, Inc. Mr. Penn has served as President of the Pennsylvania Biotechnology Association and as Co-Chair of Pennsylvania's Technology 21 Biotechnology Network. Mr. Penn holds B.S. degrees from the Massachusetts Institute of Technology in Metallurgy and Materials Science and in Industrial Management, an M.B.A. from Stanford University, and a J.D. from the University of Pennsylvania.
William A. Scott, Ph.D.
William Scott is the former Chief Executive Officer of Physiome Sciences, where he served from 1997 to 1999. Prior to joining Physiome Sciences, Dr. Scott spent thirteen years with Bristol-Meyers Squibb where he held a number of management posts, including Senior Vice President of Exploratory and Drug Discovery Research. Dr. Scott has served on the boards of eight companies including CombiChem, Inc., and currently serves on the Boards of Atherogenics, Inc. and Avalon Pharmaceuticals, Inc. Dr. Scott holds a B.Sc. in Chemistry from the University of Illinois and a Ph.D. in Biochemistry from the California Institute of Technology. Dr. Scott is an Adjunct Professor at the Rockefeller University, where he has been affiliated since 1969.
SHARE STRUCTURE - O/S Approx. 39 mil.
DGEN institutional ownership:
2009-11-12 2009-09-30 13F-HR Everett Harris And Co Institution 6,182,188 No Change
http://www.mffais.com/dgen.pk
Top Institutional HoldersConcentration of Current % Held
Everett Harris & Co. 6.2M $494,575 +53% 16.0% Low
Wells Capital ... 5.5M $387,934 +47% 14.4% Moderate
http://data.cnbc.com/quotes/DGEN/tab/8
http://www.pinksheets.com/edgar/GetFilingHtml?FilingID=6348952
courtesy of Stock Charts:http://stockcharts.com
Disclaimer The members of this board do not recommend that you buy, sell, or hold any of the stocks listed on this board.
AI
